Video
Dr. Rogers on Data for Ibrutinib in Hairy Cell Leukemia
Author(s):
Kerry Rogers, MD, discusses the results from an ongoing phase II trial investigating ibrutinib in patients with relapsed/refractory hairy cell leukemia. Because this represents a very rare patient population, accrual began in 2013, and these data reflect on a small portion of the 39 patients enrolled.
Kerry Rogers, MD, assistant professor at the Ohio State University Comprehensive Cancer Center, discusses the results from an ongoing phase II trial investigating ibrutinib (Imbruvica) in patients with relapsed/refractory hairy cell leukemia in an interview during the 2019 Hairy Cell Leukemia Foundation Annual Conference. Because this represents a very rare patient population, accrual for the trial began in 2013, and these data reflect a small portion of the 39 patients enrolled.
The overall response rate in these patients was just over 50%, says Rogers. This may not be an outstanding response, but it is promising for such a rare patient population with limited treatment options, she explains. The estimated 3-year progression-free survival (PFS) rate was just under 75%, which is very encouraging, Rogers adds. The PFS is the major benefit from ibrutinib in this patient population.
<<< View more from the 2019 Hairy Cell Leukemia Foundation Annual Conference
